Skip to Main Content

Hello, everyone, and how are you today? We are doing just fine, thank you, as we ease back into a new year. The short person has returned to the local schoolhouse and the official mascot has resumed his usual spot in the official snoozing corner. Call it the cycle of life. On that note, the time has come to fire up the coffee kettle and get cracking. So here are a few items of interest for you to peruse as you settle in yourself. Hope you have a smashing day and, as always, do keep us in mind when something saucy occurs.

Dozens of drug makers are conducting human trials for a record 89 therapies that pair antibodies with toxic agents to fight cancer, evidence of renewed confidence in an approach that has long fallen short of its promise, an analysis compiled for Reuters shows. In 2019, the Food and Drug Administration approved three antibody-drug conjugates, or ADCs, the most ever in a single year, as last-ditch treatments based on studies showing they helped patients whose survival outlook was bleak.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!